Eli Lilly appoints new chief AI officer – Pharmafile

Natalia Elliot | October 17, 2024 | Appointment | |  AI and ML, Corporate, Eli Lilly 
Eli Lilly has announced the appointment of Thomas J Fuchs as its first chief artificial intelligence (AI) officer. Fuchs’ appointment comes into effect 21 October 2024, later this month.
The role, the first of its kind at Eli Lilly, will include oversight of AI initiatives amongst the company’s activities. Such activities include clinical trials, manufacturing, drug discovery, internal functions and commercial. In his role, Fuchs will build, manage and identify AI and machine learning (ML) solutions to aid Eli Lilly with their overall goal of providing medicines to patients globally.
Diogo Rau, Lilly executive vice president and chief information and digital officer commented: “In this new era of technology, the potential for AI and ML to revolutionise health care is immense. Dr Fuchs will contribute to Lilly’s breakthroughs in AI, aiding in the discovery and development of new medicines while enhancing patient outcomes. We are committed to leveraging these cutting-edge technologies to drive innovation and make a meaningful impact on lives around the world.”
Fuchs holds a doctoral degree in ML from ETH Zurich, Switzerland, in tandem with a Master’s degree in technical mathematics from Graz Technical University, Austria. He has previously held positions at Memorial Sloan Kettering Cancer Centre, NASA’s Jet Propulsion Laboratory and The California Institute of Technology, all in the US. His more recent positions include dean and inaugural department chair for AI and Human Health at Mount Sinai, in addition to director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and Barbara T. Murphy professor for AI and computational pathology at the Icahn School of Medicine at Mount Sinai, US. Fuchs has also founded three companies, including Page AI.
Natalia Elliot
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla …
Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, …
Eli Lilly has announced that it will donate $6.5m to the United States Fund for …
Eli Lilly appoints new chief AI officer
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
Strategic alliance announced between Recipharm and Exela
Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone

source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.